Here are all the posts from the How we think section that were published in March 2016. If you don’t see the post you’re looking for here, try our search feature or looking in the tags index.
These archives are only from the How we think section, if you’re looking for the archive for our company news page, click here.
|2nd March 2016
We interviewed Wayne Atherden, Procurement Director Commercial Services at Janssen, our European procurement contact, to get a fuller understanding of his view on the issues facing brand teams and how agencies help to deliver value. Here is what he had to say.
|7th March 2016
Not all organisations are in a position to look at maturity – for some, there’s still a pressing question that needs answering: Why does content need a strategy?
In this article, Content Marketing Manager Liz Inskip and guest blogger Adwoa Baah explain how having a documented strategy for content creation, distribution, management, and governance will empower your brand teams and create organisational efficiencies.
|7th March 2016
Within the pharma and healthcare industry, the introduction of a user-centred approach that incorporates best practice user experience research and design is still rare. Often the world of user experience (UX), its activities, methods, and deliverables are not well understood within this industry.
In this article, Head of Customer Experience Elisa del Galdo breaks down how to understand the return on investment of user experience methodology.
|10th March 2016
As the wider industry becomes increasingly competitive, clients have started to become more procurement-led, looking for ways to improve margins and efficiencies in their business. The impact on agencies has been substantial, with fewer suppliers on rosters and more aggressive payment terms.
In this article, Co-Founder and Managing Director Martin Brass discusses the evolution of procurement and the new client-agency relationship.
|15th March 2016
Blue Latitude Health is now working in multiple myeloma (MM), and with each publication that emerges, it’s clear that we are witnessing a transformation in the treatment of multiple myeloma. In this article, Consultant David Cooney will take you through how that transformation has happened, and where the treatment of multiple myeloma is heading.
|30th March 2016
Healthcare is undergoing a transformative change, which presents challenges to all players in the sector. Established healthcare players like pharma need to control and shape their emerging roles.
In this article, Head of Insight Martine Leroy explores how pharma could learn from translational research organisations in adapting their approach to the changing healthcare landscape.